They demonstrated that AF had antiproliferative activity in both Bcr‐Abl wild‐type and resistant Bcr‐Abl‐T315I CML cell lines as well as in mouse IM‐resistant xenograft models, thus illustrating AF ability to overcome drug resistance. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.